Characterization of CD180 Protein Expression in Myeloid Blood C cancers
Official title: Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
Run by University Hospital, Strasbourg, France · NCT07895901 · Data updated 2026-11-12
This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | January 21, 2026 |
| Main results expected | April 21, 2027 |
| Study ends | July 21, 2027 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT07895901 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) and children (1–17) with confirmed or suspected AML who have undergone bone marrow aspiration and have available residual samples suitable for reuse.
✕Probably not a fit
Patients whose samples do not reveal relevant CD180 expression patterns or whose data cannot be correlated with clinically meaningful outcomes may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective, non-interventional study conducted at a single center to characterize CD180 expression on pathological hematopoietic cells and normal CD34+ stem/progenitor cells using flow cytometry. Residual blood and bone marrow samples collected during routine care will be analyzed alongside relevant clinical data. Samples must be introduced within 72 hours of collection, have sufficient volume, and there must be no objection to reuse of data or specimens. The goal is to understand CD180 expression patterns in AML and other myeloid malignancies to inform future diagnostic or monitoring approaches. No interventions or treatment changes are involved; the study relies on existing samples and records.
Why it matters
Potential benefit: If successful, findings could support CD180 as a diagnostic or monitoring biomarker in AML and related myeloid malignancies.
How similar studies have gone: Previous proteomic work identified CD180 as a potential target; whether flow cytometry characterization in AML translates to clinical utility remains to be determined.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients aged 18 years or older. * Pediatric patients aged 1 to 17 years. * Patients with confirmed or suspected acute myeloid leukemia who have undergone bone marrow aspiration as part of the diagnostic or relapse assessment. * Patients whose stem cells are being assessed using a blood or bone marrow sample. * Patients and/or their legal representatives, where applicable, informed by letter of the use of residual sample material for research purposes. * No written objection documented in the medical record to the reuse of personal data for scientific research. Exclusion Criteria: * Patients and/or their legal representatives, where applicable, who have objected to the reuse of personal data for scientific research. * Samples more than 72 hours old. * Clotted samples. * Samples with insufficient volume (less than 10 microliters).
Where it's running
-
Laboratoire d'Hématologie Biologique - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Laurent Mauvieux, MD, PhD
- Email: laurent.mauvieux@chru-strasbourg.fr
- Phone: 33 3 88 12 75 27
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Personalized AML: Find biomarkers to predict response to venetoclax
This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
MAX-40279 with Venetoclax and Azacitidine for unfit newly diagnosed AML
This study tests MAX-40279 added to venetoclax and azacitidine in older or unfit adults newly diagnosed with AML to see if it is safe and shows activity.
-
Venetoclax and Azacitidine Consolidation After Remission in Intermediate-Risk AML
We’re testing if a venetoclax-plus-azacitidine consolidation approach works as well as standard high-dose chemotherapy for adults with intermediate-risk AML who have already achieved remission and are headed to stem cell transplant.
-
CRD3874-SI in People with Leukemia
A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.